DeepMed Research

Valneva Austria GmbH

🇦🇹Austria

Country: 🇦🇹Austria

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.valneva.at

Clinical Trials

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Phase 3

Completed

Conditions: Chikungunya Virus Infection

Interventions: Biological: VLA1553
Biological: Placebo

First Posted Date: 2020-09-14

Last Posted Date: 2023-06-28

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 4128

Registration Number: NCT04546724

Locations: 🇺🇸
Alliance for Multispecialty Research (AMR), Norfolk, Virginia, United States
🇺🇸
Accelerated Enrollment Solutions (AES), Cincinnati, Ohio, United States
🇺🇸
Accel Research Sites - DeLand, DeLand, Florida, United States

and more 19 locations

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

Phase 2

Completed

Conditions: Enterotoxigenic Escherichia Coli Infection
Diarrhea

Interventions: Biological: VLA1701
Biological: Placebo
Other: Challenge Strain

First Posted Date: 2018-07-03

Last Posted Date: 2021-04-23

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 34

Registration Number: NCT03576183

Locations: 🇺🇸
Department of International Health Johns Hopkins University, Baltimore, Maryland, United States

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

Phase 1

Completed

Conditions: Zika Virus Infection
Zika Virus

Interventions: Biological: VLA1601
Biological: Placebo

First Posted Date: 2018-02-07

Last Posted Date: 2019-07-05

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 67

Registration Number: NCT03425149

Locations: 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Phase 1

Completed

Conditions: Chikungunya

Interventions: Biological: VLA1553

First Posted Date: 2017-12-26

Last Posted Date: 2019-08-29

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 120

Registration Number: NCT03382964

Locations: 🇺🇸
Optimal Research, LLC, Peoria, Illinois, United States

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

Phase 2

Completed

Conditions: Clostridium Difficile

Interventions: Biological: Placebo
Biological: VLA84

First Posted Date: 2014-12-15

Last Posted Date: 2017-06-08

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 500

Registration Number: NCT02316470

Locations: 🇺🇸
Optimal Research LLC, Mishawaka, Indiana, United States
🇺🇸
eStudy Site, Chula Vista, Chula Vista, California, United States
🇺🇸
eStudy Site, Oceanside, Oceanside, California, United States

and more 4 locations

Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43

Phase 2

Completed

Conditions: Pseudomonas Aeruginosa Infection

Interventions: Biological: IC43
Drug: Placebo

First Posted Date: 2012-03-26

Last Posted Date: 2016-03-31

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 803

Registration Number: NCT01563263

Locations: 🇨🇿
Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
🇩🇪
HELIOS Klinikum Wuppertal, Wuppertal, Germany
🇭🇺
University of Pecs, Pecs, Hungary

and more 47 locations

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

Phase 1

Withdrawn

Conditions: Japanese Encephalitis

Interventions: Biological: IXIARO

First Posted Date: 2012-03-21

Last Posted Date: 2013-03-08

Lead Sponsor: Valneva Austria GmbH

Registration Number: NCT01559831

Locations: 🇬🇧
UCLH Foundation Trust, London, United Kingdom

Safety Surveillance After Immunization With IXIARO

Completed

Conditions: Japanese Encephalitis

Interventions: Biological: Japanese Encephalitis Virus vaccine, inactivated, adsorbed

First Posted Date: 2011-04-14

Last Posted Date: 2015-03-10

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 20000

Registration Number: NCT01335412

Locations: 🇺🇸
Military Vaccine Agency, Alexandria, Virginia, United States

An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84

Phase 1

Completed

Conditions: Clostridium Difficile Infection

Interventions: Biological: IC84

First Posted Date: 2011-02-15

Last Posted Date: 2014-09-25

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 82

Registration Number: NCT01296386

Locations: 🇭🇺
St. Imre Teaching Hospital, Budapest, Hungary
🇦🇹
Privatklinik Leech, Graz, Austria
🇦🇹
Medizinische Universität Wien, Vienna, Austria

Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country

Phase 3

Completed

Conditions: Japanese Encephalitis

Interventions: Biological: IXIARO

First Posted Date: 2011-02-15

Last Posted Date: 2014-12-19

Lead Sponsor: Valneva Austria GmbH

Target Recruit Count: 300

Registration Number: NCT01296360

Locations: 🇵🇭
Research Institute for Tropical Medicine - Clinical Research Division, Muntinlupa City, Alabang, Philippines
🇵🇭
Research Institute for Tropical Medicine, Muntinlupa City, Alabang, Philippines
🇵🇭
UP-Philippine General Hospital, Manila, Philippines

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy